German vaccine manufacturer BioNTech has found a successor to take over as chief executive officer from co-founder Uğur Şahin. Guido Oelkers will take up the post by February 1 next year at the latest ...

Lower global demand for the Covid-19 vaccine has cost BioNTech a loss running into the billions in the first half of 2026. The German company made a net loss of €1.

German biopharmaceutical company CureVac sued BioNTech on Tuesday, seeking "fair compensation" for alleged infringement of intellectual property rights related to the mRNA technology that was used to ...

BERLIN, Aug 4 (Reuters) - German vaccine maker BioNTech significantly lowered its full year sales outlook range on Tuesday ...

German biotech BioNTech today reported financial results for the three and six months ended June 30, 2026 and provided an update on its corporate progress. The firm’s shares were down 3.4% at $89.11 ...

BioNTech SE BNTX is reportedly scheduled to appear in court on Monday to defend itself against a lawsuit filed by a German woman seeking damages for alleged side effects of BioNTech's COVID-19 vaccine ...

BERLIN, Jan 11 (Reuters) - BioNTech 22UAy.DE has filed a motion to have a German patent held by competitor CureVac 5CV.DE declared invalid in response to a patent lawsuit filed by CureVac last year, a ...

BEIJING (Reuters) -A shipment of BioNTech COVID-19 vaccines for German nationals in China have arrived at the German embassy in Beijing, an embassy spokesperson told Reuters on Friday. "We can now ...

In just two short years, BioNTech will have more than doubled the size of its workforce at the German biologics facility it bought from Novartis at the height of the pandemic. BioNTech is hiking the ...

BERLIN (Reuters) -BioNTech will invest 40 million euros ($43 million) in a new facility in Germany that will allow it to produce an important building block in mRNA-based drugs, the German ...